Skip to main content

International Journal of Clinical Oncology

Ausgabe 1/2015

Inhalt (29 Artikel)

Introduction to Review Articles

Cancer registration system: an introduction

Tomotaka Sobue

Review Article

Cancer registries in Japan: National Clinical Database and site-specific cancer registries

Takayuki Anazawa, Hiroaki Miyata, Mitsukazu Gotoh

Original Article

Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features

Yu Jin Lim, Il Han Kim, Tae Jin Han, Seung Hong Choi, Sung-Hye Park, Chul-Kee Park, Sun Ha Paek, Se-Hoon Lee, Tae Min Kim

Original Article

Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience

Keishi Makino, Hideo Nakamura, Taku-ichiro Hide, Jun-ichiro Kuroda, Shigetoshi Yano, Jun-ichi Kuratsu

Original Article

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya, Yoshiyuki Osamura, Shin-etsu Kamata, Kouki Miura, Chihiro Fushimi, Hideaki Takahashi, Daisuke Kawakita, Seiji Kishimoto, Toshitaka Nagao

Original Article

Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis

Shinsaku Yamaguchi, Takayuki Ohguri, Yuichi Matsuki, Katsuya Yahara, Hodaka Oki, Hajime Imada, Hiroyuki Narisada, Yukunori Korogi

Original Article

Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience

Tadamasa Yoshitake, Katsumasa Nakamura, Yoshiyuki Shioyama, Tomonari Sasaki, Saiji Ohga, Makoto Shinoto, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Yoshio Matsuo, Shingo Baba, Hiroshi Honda

Original Article

The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer

Shane Dormady, Michael S. Broder, Girish V. Putcha, Robert H. Dumanois, Alison H. DeCristofaro, Eunice Chang, Paul R. Billings, Thierry Jahan

Original Article

Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?

Ahmet Dirican, Betul Bolat Kucukzeybek, Ahmet Alacacioglu, Yuksel Kucukzeybek, Cigdem Erten, Umut Varol, Isil Somali, Lutfiye Demir, Ibrahim Vedat Bayoglu, Yasar Yildiz, Murat Akyol, Betul Koyuncu, Eyup Coban, Eda Ulger, Fulya Cakalagaoglu Unay, Mustafa Oktay Tarhan

Original Article

Perception and needs of reproductive specialists with regard to fertility preservation of young breast cancer patients

Chikako Shimizu, Tomoyasu Kato, Nobuko Tamura, Hiroko Bando, Yoshimasa Asada, Yuri Mizota, Seiichiro Yamamoto, Yasuhiro Fujiwara

Original Article

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series

Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, Franco Nolè, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri, Aron Goldhirsch

Original Article

Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001)

Mitsuo Shimada, Yuji Morine, Hiroaki Nagano, Etsuro Hatano, Takashi Kaiho, Masaru Miyazaki, Toru Kono, Toshiya Kamiyama, Satoshi Morita, Junichi Sakamoto, Mitsuo Kusano, Shigetoyo Saji, Takashi Kanematsu, Masaki Kitajima

Original Article

Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy

Noriyuki Akutsu, Shigeru Sasaki, Hideyasu Takagi, Masayo Motoya, Masahiro Shitani, Mai Igarashi, Daisuke Hirayama, Hideki Wakasugi, Hiroyuki Yamamoto, Hiroyuki Kaneto, Kazuhiko Yonezawa, Atsushi Yawata, Takeya Adachi, Yasuo Hamamoto, Yasuhisa Shinomura

Original Article

Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study

Toshihiko Matsumoto, Tomohiro Nishina, Minoru Mizuta, Akihito Tsuji, Ryouhei Watanabe, Ikuo Takahashi, Yuji Watanabe, Toshikazu Moriwaki, Takashi Maeba, Ichinosuke Hyodo

Original Article

Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects

Toshihiro Komura, Koh Miura, Tetsuhiko Shirasaka, Shinobu Ohnuma, Miki Shimada, Taiki Kajiwara, Fumiyoshi Fujishima, Alex Philchenkov, Kei Nakagawa, Katsuyoshi Kudoh, Sho Haneda, Masahide Toshima, Atsushi Kohyama, Hiroaki Musha, Takeshi Naitoh, Chikashi Shibata, Michiaki Unno

Original Article

Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia

Takashi Iwata, Takuma Fujii, Kenji Morii, Miyuki Saito, Juri Sugiyama, Hiroshi Nishio, Tohru Morisada, Kyoko Tanaka, Tomonori Yaguchi, Yutaka Kawakami, Daisuke Aoki

Original Article

Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens: a Japanese Gynecologic Oncology Group study

Takuma Fujii, Miyuki Saito, Toshihiko Hasegawa, Takashi Iwata, Hiroyuki Kuramoto, Kaneyuki Kubushiro, Mineo Ohmura, Kazunori Ochiai, Hiroharu Arai, Masaru Sakamoto, Teiichi Motoyama, Daisuke Aoki

Original Article

Clinical features of long-term survivors of recurrent epithelial ovarian cancer

Haruko Iwase, Toshio Takada, Chiaki Iitsuka, Hidetaka Nomura, Akiko Abe, Tomoko Taniguchi, Kimihiko Sakamoto, Ken Takizawa, Nobuhiro Takeshima

Original Article

Preoperative differentiation between benign and malignant renal masses smaller than 4 cm treated with partial nephrectomy

Masatomo Nishikawa, Hideaki Miyake, Kazuhiro Kitajima, Satoru Takahashi, Kazuro Sugimura, Masato Fujisawa

Original Article

Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy

Kazutoshi Fujita, Motohide Uemura, Yoshiyuki Yamamoto, Go Tanigawa, Wataru Nakata, Mototaka Sato, Akira Nagahara, Hiroshi Kiuchi, Yasutomo Nakai, Kiyomi Matsumiya, Seiji Yamaguchi, Norio Nonomura

Original Article

Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence

Hitoshi Inoue, Kensaku Nishimura, Seiji Yamaguchi, Norio Nonomura, Tsuneo Hara

Original Article

Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy

Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa

Original Article

A statistical study on malignant melanoma over the past 12 years in Fukui University Hospital

Masato Yasuta, Suguru Sato, Sachio Kouraba, Shiro Iino, Takahiro Kiyohara

Original Article

Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases

Yoshitsugu Shibayama, Shinichi Imafuku, Akira Takahashi, Juichiro Nakayama

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.